Claims:

1. Use of a suspension of liver cells in the manufacture of a medicament for use in a method of treatment of an individual with a diseased or damaged liver comprising;

administering a suspension of liver cells to the biliary tree of the liver in the direction of decreasing biliary duct diameter, such that the liver cells engraft into the liver.

2. The use of claim 1 wherein the liver cells in the suspension are in the form of aggregates.

3. The use of claim 1 or 2 wherein the liver cells are suspended in a culture medium comprising a buffer and a Rho kinase inhibitor.

4. The use according to claim 7 wherein the culture medium further comprises an anti-choleretic agent and/or a non-adhesive reagent.

5. The use of any one of claims 1 to 4 wherein the liver cells are cholangiocytes.

6. The use of any one of claims 1 to 5 wherein the method comprises measuring the volume of the biliary tree of the individual up to a desired site of engraftment and suspending the liver cells in a volume corresponding to the volume measured for the individual.

7. The use according to claim 6, wherein the volume of the biliary tree of the individual is measured by;

administering a fluid comprising a contrast agent into the biliary tree of the individual until the desired site of engraftment is visible in on imaging, and

determining the injected volume of the contrast agent fluid.

8. The use according to claim 7, wherein the volume of the biliary tree of the individual is measured by MR imaging.

9. The use of any one of claims 1to 8wherein the method comprises flushing the biliary tree of the liver with a wash solution comprising a buffer before administration of the suspension of liver cells.

10. The use according to claim 9 wherein the pH of the biliary tree following said flushing is non-toxic to the administered liver cells.

11. The use according to claim 9 or 10 wherein said flushing removes diseased or damaged cells at the site of engraftment.

12. The use of any one of claims 1 to 11 further comprising administering to the individual an anti-choleretic agent to reduce bile secretion.

13. The use of any one of claims 1 to 12 wherein the cell suspension is injected into the biliary tree through a catheter or cannula.

14. The or use according to claim 13 wherein the interior surface of the catheter or cannula is coated with protein to prevent cell adhesion.

15. The use according to any one of claims 1 to 14 wherein the method comprises retaining the suspension of liver cells within the biliary tree following said administration.

16. The use according to claim 15 wherein the suspension of liver cells is retained in the biliary tree by occluding the lumen of a bile duct of said tree to reduce or prevent egress of the suspension.

17. The use according to claim 16 wherein the biliary tree is occluded by inflating a balloon in said duct.

18. The use according to claim 17 wherein the biliary tree is occluded by biodegradable beads.

19. The use according to any one of claims to 1 to 18 wherein the biliary tree is occluded for 30 minutes or longer.

20. The use according to any one of claims 1 to 19 wherein the method comprises monitoring the pH, electrolyte content and/or volume of the bile produced in said liver following said administration, wherein an increase in pH, electrolyte content and/or volume of the bile is indicative that the liver cells are engrafted.